SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as its strong Q4 earnings, profitability, and new share buyback authorization have ironically led to a significant stock decline, sparking widespread frustration among investors. The community is fiercely debating whether ongoing stock-based compensation and dilution are overshadowing the company's growth in subscriptions and long-term potential in AI/AR smartglasses.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health ($OSCR) is trending after the House passed a bill to extend ACA subsidies, sparking intense community debate on its potential for future growth and profitability, with investors keenly focused on the upcoming earnings report and crucial 2026 guidance amidst broader healthcare sector sentiment.

Dynatrace, Inc. engages in the advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. The company was founded by Bernd Greifeneder in 2005 and is headquartered in Boston, MA.

Dynatrace Inc

Dynatrace is trending following its strong Q3 fiscal year 2026 earnings report, which surpassed expectations across key metrics and included the authorization of a $1 billion share repurchase program. This positive financial performance and commitment to shareholder returns are fueling optimistic discussions among the community, despite some recent analyst target adjustments.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as recent FDA action against "copycat" GLP-1 compounded drugs highlights the value of legitimate innovation, while strong results from Eli Lilly intensify pressure on competitors like Novo Nordisk, who the community believes urgently need Viking's "best-in-class" VK2735 asset to remain competitive in the rapidly expanding obesity market.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, an SEC investigation, and disclosures of material weaknesses in internal controls and a lowered fiscal outlook. The community is sharply divided, with many voicing deep concerns about potential fraud and a continued decline, while others are aggressively buying the significant dip, anticipating an oversold rebound.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending intensely as the community eagerly anticipates its upcoming earnings, fueling a polarized debate on whether new leadership can deliver a crucial turnaround or if the stock faces continued pressure amidst broader fintech sector challenges.

Investment Managers Series Trust II - Tradr 2X Long CRML Daily ETF

Tradr 2X Long CRML Daily ETF

Tradr's recently launched 2X leveraged ETF, $CRMX, tracking Critical Metals ($CRML) and its rare earth projects, is actively discussed as traders debate its actual leverage performance and monitor for a potential breakout from quiet accumulation on increased volume. Many are closely watching its tight consolidation and small float dynamics for an upward move.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork (UPWK) is trending sharply lower after providing a weaker-than-expected outlook, despite reporting a beat on its recent earnings. The community is actively debating if the platform is becoming obsolete due to advancing AI technology, while some view the sell-off as an overreaction and a buying opportunity.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending due to the FDA's Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns over trial design, including natural history controls and the surrogate endpoint. This decision has ignited community debate, with many investors anticipating a substantial stock drop and others expressing frustration over the FDA's stringent approach to rare disease gene therapies.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following strong Q4 2025 financial results and positive FY26 guidance, bolstered by recent FDA approvals for its oncology blockbusters Enhertu and Datroway, and groundbreaking Phase 3 data for hypertension treatment Baxdrostat. The community is actively discussing the company's strategic direct listing on the NYSE, along with significant investments in US manufacturing and an expanding obesity pipeline in China, all signaling a robust long-term growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

Shares of Inozyme Pharma, Inc. (INZY) rocketed 179% on Friday after BioMarin Pharmaceutical (BMRN) agreed to <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.inozyme.com/news-releases/news-release-details/biomarin-strengthens-enzyme-therapy-business-acquisition-inozyme">acquire</a> the company for $270 million.Under the deal, BioMarin will acquire Inozyme for $4 per share in an all-cash transaction. The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.BioMarin will commence a cash tender to acquire all of Inozyme's outstanding shares. A majority of the outstanding shares must be tendered for its consummation.Inozyme's Board of Directors unanimously recommended that shareholders tender their shares in the offer.Following the successful completion of the tender offer, a wholly-owned subsidiary of BioMarin will merge with Inozyme. The transaction is expected to close in the third quarter of 2025.BioMarin said that it expects the acquisition to strengthen its enzyme therapies portfolio.Inozyme’s late-stage enzyme replacement therapy, INZ-701, is currently being assessed for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 deficiency (ENPP1), a rare genetic disorder caused by mutations in the ENPP1 gene, leading to loss of ENPP1 enzymatic activity. Currently, there are no approved therapies for ENPP1 Deficiency, Inozyme said.BioMarin CEO Alexander Hardy said that the company will continue to evaluate both external and internal innovation going forward.“We are in a strong financial position to bring in additional assets as we accelerate the development of medicines for patients with significant unmet need," he said.On Stocktwits, retail sentiment around Inozyme jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_12_31_33_PM_png_8f9ddbb20d.webp" alt="INZY's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits" width="628" height="60"><figcaption>INZY's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure>For BioMarin, retail sentiment around the company fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_12_32_33_PM_png_3cde3c49bc.webp" alt="BMRN's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>BMRN's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/INZY">INZY stock</a> has gained by 39% this year but has fallen by nearly 16% over the past 12 months.<a href="https://stocktwits.com/symbol/BMRN">BMRN stock</a> is trading nearly 2% higher as of Friday noon.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/volkswagen-shareholders-flag-governance-issues-at-car-company/chiwBRDRbnU">Volkswagen Shareholders Flag Governance Issues At Carmaker, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.

Inozyme Stock Rockets 178% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

Equity

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.


Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Inozyme Pharma Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

INZY
Inozyme Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INZY News

INZYInozyme Pharma Inc